Methotrexate for Rheumatoid Arthritis: A Guide from Canada

REFERENCES

1. 1.↵
   1. Weinblatt ME,
   2. Coblyn JS,
   3. Fox DA,
   4. Fraser PA,
   5. Holdsworth DE,
   6. Glass DN,
   7. et al.

   Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818–22.

   OpenUrlPubMed
2. 2.↵
   1. Williams HJ,
   2. Willkens RF,
   3. Samuelson CO Jr,
   4. Alarcon GS,
   5. Guttadauria M,
   6. Yarboro C,
   7. et al.

   Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28:721–30.

   OpenUrlPubMed
3. 3.↵
   1. Paulus HE

   . FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma. Arthritis Rheum 1986;29:1289–90.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Combe B,
   2. Landewe R,
   3. Lukas C,
   4. Bolosiu HD,
   5. Breedveld F,
   6. Dougados M,
   7. et al.

   EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Visser K,
   2. Katchamart W,
   3. Loza E,
   4. Martinez-Lopez JA,
   5. Salliot C,
   6. Trudeau J,
   7. et al.

   Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086–93.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Katchamart W,
   2. Bourré-Tessier J,
   3. Donka T,
   4. Drouin J,
   5. Rohekar G,
   6. Bykerk VP,
   7. the Canadian 3E Initiative Consensus Group

   . Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol 2010;37:1422–30.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Chakravarty K,
   2. McDonald H,
   3. Pullar T,
   4. Taggart A,
   5. Chalmers R,
   6. Oliver S,
   7. et al.

   BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008; 47:924–5.

   OpenUrlFREE Full Text
8. 8.↵
   1. Hoekstra M,
   2. van Ede AE,
   3. Haagsma CJ,
   4. van de Laar MA,
   5. Huizinga TW,
   6. Kruijsen MW,
   7. et al.

   Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Hider SL,
   2. Silman AJ,
   3. Thomson W,
   4. Lunt M,
   5. Bunn D,
   6. Symmons DP

   . Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 2009;68:57–62.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Wessels JA,
    2. de Vries-Bouwstra JK,
    3. Heijmans BT,
    4. Slagboom PE,
    5. Goekoop-Ruiterman YP,
    6. Allaart CF,
    7. et al.

    Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087–95.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Hamilton RA,
    2. Kremer JM

    . Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86–90.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Hoekstra M,
    2. Haagsma C,
    3. Neef C,
    4. Proost J,
    5. Knuif A,
    6. van de Laar M

    . Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31:645–8.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Pandya S,
    2. Aggarwal A,
    3. Misra R

    . Methotrexate twice weekly vs once weekly in rheumatoid arthritis: a pilot double-blind, controlled study. Rheumatol Int 2002;22:1–4.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Fransen J,
    2. Moens HB,
    3. Speyer I,
    4. van Riel PL

    . Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294–8.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Grigor C,
    2. Capell H,
    3. Stirling A,
    4. McMahon AD,
    5. Lock P,
    6. Vallance R,
    7. et al.

    Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Verstappen SM,
    2. Jacobs JW,
    3. van der Veen MJ,
    4. Heurkens AH,
    5. Schenk Y,
    6. ter Borg EJ,
    7. et al.

    Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443–9.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Harley CR,
    2. Frytak JR,
    3. Tandon N

    . Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9 Suppl:S136–S143.

    OpenUrlPubMed
18. 18.↵
    1. Homer D,
    2. Nightingale P,
    3. Jobanputra P

    . Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. Musculoskeletal Care 2009;7:78–92.

    OpenUrlCrossRefPubMed